Equities

Panbela Therapeutics Inc

PBLA:QBB

Panbela Therapeutics Inc

Actions
  • Price (USD)0.40
  • Today's Change0.020 / 5.24%
  • Shares traded28.39k
  • 1 Year change-99.70%
  • Beta0.9022
Data delayed at least 15 minutes, as of May 31 2024 20:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.

  • Revenue in USD (TTM)0.00
  • Net income in USD-27.26m
  • Incorporated2011
  • Employees7.00
  • Location
    Panbela Therapeutics Inc712 Vista Blvd # 305WACONIA 55387United StatesUSA
  • Phone+1 (952) 479-1196
  • Websitehttps://panbela.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dermata Therapeutics Inc0.00-8.69m1.70m8.00--6.71-----24.67-24.670.000.57170.00----0.00-120.05---146.08--------------0.00------18.90------
Qualigen Therapeutics Inc0.00-12.48m1.70m4.00---------2.46-2.640.00-0.39230.00----0.00-118.15---364.72--21.30---------7.41--------10.22------
PainReform Ltd0.00-12.54m1.76m6.00--0.7109-----7.77-7.770.000.99880.00----0.00-158.88-55.47-222.89-68.20------------0.00-------6.28------
Hi-Great Group Holding Co109.49k-121.76k1.78m--------16.26-0.0012-0.00120.0011-0.00110.82240.8406-----91.46------46.50---111.21--0.0144-52.41-----47.32---3,789.70------
SYBLEU Inc11.70k-307.88k1.84m--------157.17-0.0293-0.02930.0011-0.03670.0641-------168.63-----------2,631.45-----8.484.96--0.00--26.51------
SOHM Inc-100.00bn-100.00bn1.84m--------------------------------------------------------------
CanaQuest Medical Corp0.00-808.07k1.92m-----------0.0514-0.05140.00-0.0370.00-------1,084.38--------------------------57.42------
Panbela Therapeutics Inc0.00-27.26m1.94m7.00---------20.38-20.380.00-0.65630.00----0.00-201.94-215.89-809.38-476.38-----------161.794.16------27.68------
Twinlab Consolidated Holdings Inc12.65m-9.55m1.94m17.00------0.1537-0.0369-0.05020.0488-0.54471.011.497.30743,941.20-76.13-60.53----34.5921.36-75.51-37.720.0094-0.0108-----20.87-28.58-20.28------
VG Life Sciences Inc0.00-4.30m2.11m7.00---------0.0721-0.07210.00-0.04910.00-------384.41-294.08-----------587,591.90---1.70--------16.58------
America Great Health219.13k-859.20k2.11m7.00------9.64-0.00004-0.000040.00001-0.00020.67460.072118.1631,304.29-265.62-543.96----95.92-247.36-393.74-1,193.550.035-1.37----95.23--84.35------
Windtree Therapeutics Inc0.00-5.96m2.11m15.000.19270.1181----18.5318.530.0030.230.00----0.00-18.26-44.51-20.72-48.38-------94,533.34----0.00------48.25------
Link Reservations Inc0.00-480.90k2.11m0.00---------46.51-46.510.00-13.990.00-------246.84-----------------2.43---------22.69------
CYANOTECH CORP22.49m-4.62m2.12m86.00--0.1518--0.0941-0.7265-0.72653.532.010.78891.5310.73261,546.50-16.19-2.32-21.07-2.9629.5935.88-20.52-2.330.3702-5.930.3299---35.56-7.44-259.70--1.22--
American Green Inc-100.00bn-100.00bn2.14m6.00------------------------------------------------------------
Data as of May 31 2024. Currency figures normalised to Panbela Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Woodbury Financial Services, Inc.as of 31 Dec 20234.000.00%
Tower Research Capital LLCas of 31 Mar 20240.000.00%
Citadel Securities LLCas of 31 Mar 20240.000.00%
Geode Capital Management LLCas of 31 Mar 20240.000.00%
Two Sigma Securities LLCas of 31 Mar 20240.000.00%
HRT Financial LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.